Einzeltreffer — DigiBib

The present study aimed at evaluating the YF-specific neutralizing antibody profile besides a multiparametric analysis of phenotypic/functional features of cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF vaccine, administered as a single subcutaneous injection. The immunological parameters of each volunteer was monitored at two time points, referred as: before (Day 0) [Non-Vaccinated, NV (D0) ] and after vaccination (Day 30-45) [Primary Vaccinees, PV (D30-45) ]. Data demonstrated high levels of neutralizing antibodies for PV (D30-45) leading to a seropositivity rate of 93%. A broad increase of systemic soluble mediators with a mixed profile was also observed for PV (D30-45) , with IFN-γ and TNF-α presenting the highest baseline fold changes. Integrative network mapping of soluble mediators showed increased correlation numbers in PV (D30-45) as compared to NV (D0) (532vs398). Moreover, PV (D30-45) exhibited increased levels of Terminal Effector (CD45RA + CCR7 - ) CD4 + and CD8 + T-cells and Non-Classical memory B-cells (IgD + CD27 + ). Dimensionality reduction of Mass Cytometry data further support these findings. A polyfunctional cytokine profile (TNF-α/IFN-γ/IL-10/IL-17/IL-2) of T and B-cells was observed upon in vitro antigen recall. Mapping and kinetics timeline of soluble mediator signatures for PV (D30-45) further confirmed the polyfunctional profile upon long-term in vitro culture, mediated by increased levels of IFN-γ and TNF-α along with decreased production of IL-10. These findings suggest novel insights of correlates of protection elicited by the 1/5 fractional dose of 17DD-YF vaccine.

Titel:	Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults.
Autor/in / Beteiligte Person:	Reis, LR ; Costa-Rocha, IA ; Abdala-Torres, T ; Campi-Azevedo, AC ; Peruhype-Magalhães, V ; Araújo, MSS ; Spezialli, E ; do Valle Antonelli LR ; da Silva-Pereira RA ; Almeida, GG ; Fernandes, EG ; Fantinato, FFST ; Domingues, CMAS ; Lemos, MCF ; Chieppe, A ; Lemos, JAC ; Coelho-Dos-Reis, JG ; de Lima SMB ; de Souza Azevedo A ; Schwarcz, WD ; Camacho, LAB ; de Lourdes de Sousa Maia M ; de Noronha TG ; Duault, C ; Rosenberg-Hasson, Y ; Teixeira-Carvalho, A ; Maecker, HT ; Martins-Filho, OA
Link:	Full Text Finder (Volltext)
Zeitschrift:	Scientific reports, Jg. 14 (2024-04-02), Heft 1, S. 7709
Veröffentlichung:	London : Nature Publishing Group, copyright 2011-, 2024
Medientyp:	academicJournal
ISSN:	2045-2322 (electronic)
DOI:	10.1038/s41598-024-57645-3
Schlagwort:	Humans Adult Antibodies, Neutralizing Interleukin-10 Antibodies, Viral Tumor Necrosis Factor-alpha CD8-Positive T-Lymphocytes Vaccination Yellow Fever Vaccine Yellow Fever
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Corporate Authors: Collaborative Group for Studies of Yellow Fever Vaccine Publication Type: Journal Article Language: English [Sci Rep] 2024 Apr 02; Vol. 14 (1), pp. 7709. <i>Date of Electronic Publication: </i>2024 Apr 02. MeSH Terms: Yellow Fever Vaccine* ; Yellow Fever* ; Humans ; Adult ; Antibodies, Neutralizing ; Interleukin-10 ; Antibodies, Viral ; Tumor Necrosis Factor-alpha ; CD8-Positive T-Lymphocytes ; Vaccination References: Epidemiol Serv Saude. 2017 Jul-Sep;26(3):617-620. (PMID: 28977185) ; PLoS Pathog. 2013;9(6):e1003458. (PMID: 23818856) ; Ann Intern Med. 2018 Dec 4;169(11):761-765. (PMID: 30476963) ; Lancet Infect Dis. 2001 Aug;1(1):11-20. (PMID: 11871403) ; Hum Vaccin Immunother. 2016;12(2):491-502. (PMID: 26360663) ; JAMA Ophthalmol. 2019 Sep 01;137(9):996-1002. (PMID: 31219512) ; Trends Microbiol. 2018 Nov;26(11):913-928. (PMID: 29933925) ; Emerg Infect Dis. 2019 Aug;25(8):1511-1521. (PMID: 31298654) ; BMJ. 2016 Jul 15;354:i3764. (PMID: 27422309) ; J Immunol. 2009 Dec 15;183(12):7919-30. (PMID: 19933869) ; Vaccine. 2011 Jan 10;29(3):583-92. (PMID: 20732465) ; N Engl J Med. 2019 Aug 1;381(5):444-454. (PMID: 29443626) ; Vaccine. 2022 Jan 31;40(5):798-810. (PMID: 34969545) ; PLoS Negl Trop Dis. 2018 Jun 7;12(6):e0006462. (PMID: 29879134) ; J Clin Virol. 2015 Mar;64:160-73. (PMID: 25453327) ; J Immunol Methods. 2023 Nov;522:113568. (PMID: 37748728) ; Bio Protoc. 2015 Jan 5;5(1):. (PMID: 29104886) ; Clin Exp Immunol. 2007 Apr;148(1):90-100. (PMID: 17309541) ; Hum Vaccin Immunother. 2013 Apr;9(4):879-88. (PMID: 23364472) ; Lancet. 2018 Feb 3;391(10119):402. (PMID: 29407015) ; PLoS One. 2008 Apr 23;3(4):e1993. (PMID: 18431480) ; BMC Infect Dis. 2014 Jul 15;14:391. (PMID: 25022840) ; Biologicals. 2012 Nov;40(6):399-404. (PMID: 23034357) ; Vaccine. 2014 Sep 3;32(39):4977-84. (PMID: 25090646) ; Vaccine. 2017 Oct 13;35(43):5751-5752. (PMID: 28689653) ; PLoS One. 2012;7(12):e49828. (PMID: 23251351) ; J Immunol Methods. 2017 Sep;448:9-20. (PMID: 28514646) Contributed Indexing: Investigator: DA Otta; OA Martins-Filho ; Keywords: 17DD vaccine; Adults; Cellular memory; Fractional dose; Neutralizing antibodies; Yellow fever Substance Nomenclature: 0 (Antibodies, Neutralizing) ; 0 (Yellow Fever Vaccine) ; 130068-27-8 (Interleukin-10) ; 0 (Antibodies, Viral) ; 0 (Tumor Necrosis Factor-alpha) Entry Date(s): Date Created: 20240402 Date Completed: 20240404 Latest Revision: 20240405 Update Code: 20240405 PubMed Central ID: PMC10987530

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults.